Clinical analysis of montelukast combined with doxofylline in older bronchial asthma
10.3760/cma.j.issn.1673-4904.2013.30.006
- VernacularTitle:孟鲁司特联合多索茶碱治疗老年支气管哮喘的临床分析
- Author:
Wei LI
- Publication Type:Journal Article
- Keywords:
Asthma;
Aged;
Montelukast;
Doxofylline
- From:
Chinese Journal of Postgraduates of Medicine
2013;36(30):14-16
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical effect of orally montelukast combined with doxofylline in older bronchial asthma.Methods A total of 87 stationary phase older bronchial asthma patients were divided into trial group (44 cases) and control group (43 cases).Trial group was given orally montelukast 10 mg 1 time/d,doxofylline 0.2 g,2 times/d.Control group was given inhaled fluticasone 250 μ g,2 times/d,a total of 3 months.The forced expiratory volume in one second (FEV1),peak expiratory flow rate (PEFR),one second rate (FEV1/FVC),asthma control test (ACT) score and the adverse reaction were compared between the 2 groups.Results There were no significant differences in FEV1,PEFR,FEV1/FVC before treatment between the 2 groups (P ＞ 0.05),they were significantly improved after treatment [trial group:(2.20 ± 3.21)L vs.(1.68 ± 0.71) L,(3.97 ± 0.32) L/s vs.(3.27 ± 0.32) L/s,(76.18 ± 1.02)％ vs.(63.91 ± 1.40)％,control group:(2.24 ±0.75) L vs.(1.71 ± 1.58) L,(4.06 ±0.34) L/s vs.(3.29 ±0.28) L/s,(77.85 ±0.67)％ vs.(62.37 ± 1.29)％],there were statistical differences (P ＜ 0.05).But there were no statistical differences after treatment between the 2 groups (P＞ 0.05).According ACT score,total effective rate in trial group was 90.9％ (40/44),in control group was 95.3％(41/43),there was no statistical difference (P ＞ 0.05).The rates of adverse reaction in trial group and control group were 4.5％(2/44) and 7.0％(3/43),there was no statistical difference (P ＞ 0.05).Conclusions The curative effect of orally montelukast combined with doxofylline in older bronchial asthma closes to the classic solution of inhalation fluticasone,which is easily accepted by older patients,and safety.It provides another option for older bronchial asthma patients.
